Literature DB >> 8325902

The role of platinum dose intensity in the management of ovarian cancer.

M Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8325902     DOI： 10.1007/bf01686459

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  10 in total

1.  The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.

Authors:  D M Gershenson; M F Mitchell; N Atkinson; E G Silva; J J Kavanagh; M Morris; T W Burke; D Warner; J T Wharton
Journal:  Gynecol Oncol       Date:  1992-10       Impact factor: 5.482

2.  cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  P A Andrews; S Velury; S C Mann; S B Howell
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer.

Authors:  M C Palmer; E Shepert; A Schepansky; G D MacLean
Journal:  Int J Gynecol Cancer       Date:  1992-11       Impact factor: 3.437

4.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

Authors:  D I Jodrell; M J Egorin; R M Canetta; P Langenberg; E P Goldbloom; J N Burroughs; J L Goodlow; S Tan; E Wiltshaw
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

5.  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.

Authors:  S B Kaye; C R Lewis; J Paul; I D Duncan; H K Gordon; H C Kitchener; D J Cruickshank; R J Atkinson; M Soukop; E M Rankin
Journal:  Lancet       Date:  1992-08-08       Impact factor: 79.321

6.  High-dose cisplatin in hypertonic saline.

Authors:  R F Ozols; B J Corden; J Jacob; M N Wesley; Y Ostchega; R C Young
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

7.  A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group.

Authors:  H Y Ngan; Y C Choo; M Cheung; L C Wong; H K Ma; R Collins; C Fung; C S Ng; V Wong; H C Ho
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

8.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

Authors:  L Levin; W M Hryniuk
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

9.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

10.  Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.

Authors:  J P Neijt; W W ten Bokkel Huinink; M E van der Burg; A T van Oosterom; P H Willemse; J B Vermorken; A C van Lindert; A P Heintz; E Aartsen; M van Lent
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162
  10 in total
  1 in total

1.  Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

Authors:  J H Schellens; J Ma; A S Planting; M E van der Burg; E van Meerten; M de Boer-Dennert; P I Schmitz; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.